EAU 2025 | 100% Specificity Achieved! Qilu Hospital of Shandong University’s “Non-Biopsy” Prostate Cancer Study Presented as Oral Report

EAU 2025 | 100% Specificity Achieved! Qilu Hospital of Shandong University’s “Non-Biopsy” Prostate Cancer Study Presented as Oral Report

Prostate biopsy remains the gold standard for diagnosing prostate cancer, but it carries risks such as infection, bleeding, and urinary obstruction. As a result, growing research interest has focused on developing “non-biopsy” diagnostic strategies. At the 2025 Annual Meeting of the European Association of Urology (EAU25), a study led by Professor Shouzhen Chen and Professor Benkang Shi from Qilu Hospital of Shandong University was selected for oral presentation. The study demonstrated that combining PSMA PET/CT, multiparametric MRI (PI-RADS score), and blood biomarkers—PHI and PSAD—can reduce the prostate cancer missed diagnosis rate to zero.
Professors Jeremy Teoh and Yige Bao Share Research Highlights and Clinical Insights, as “Chinese Excellence” Shines on Europe’s Academic Stage

Professors Jeremy Teoh and Yige Bao Share Research Highlights and Clinical Insights, as “Chinese Excellence” Shines on Europe’s Academic Stage

With diagnostic and therapeutic technologies advancing rapidly, precision treatment strategies for genitourinary malignancies such as urothelial carcinoma and prostate cancer are evolving with growing momentum. At the recent 2025 Annual Meeting of the European Association of Urology (EAU25), Professor Jeremy Teoh of The Chinese University of Hong Kong and Professor Yige Bao of West China Hospital, Sichuan University both presented major findings or received distinguished honors, showcasing the academic strength and international influence of Chinese urologists.  UroStream invited both experts for an insightful conversation on their research, clinical progress, and evolving strategies in the treatment of urothelial and prostate cancers.